Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 18;28(18):4003–4017. doi: 10.1158/1078-0432.CCR-21-3648

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2022 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 4. Kaplan–Meier plot of progression-free survival. A, Tafasitamab plus lenalidomide versus systemic therapies pooled. B, Tafasitamab plus lenalidomide versus BR. C, Tafasitamab plus lenalidomide versus R-GemOx. BR, bendamustine + rituximab; CI, confidence interval; HR, hazard ratio; KM; Kaplan–Meier; LEN; lenalidomide; R-GemOx, rituximab + gemcitabine + oxaliplatin; Tafa, tafasitamab. — Kaplan–Meier plot of progression-free survival. A, Tafasitamab plus lenalidomide versus systemic therapies pooled. B, Tafasitamab plus lenalidomide versus BR. C, Tafasitamab plus lenalidomide versus R-GemOx. BR, bendamustine + rituximab; CI, confidence interval; HR, hazard ratio; KM; Kaplan–Meier; LEN; lenalidomide; R-GemOx, rituximab + gemcitabine + oxaliplatin; Tafa, tafasitamab.